Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Biologic Imaging Reagents Market To Double

By HospiMedica International staff writers
Posted on 22 Jan 2009
According to a new technical market research report, the global market for biologic imaging reagent technology is expected to be worth US$5.8 billion in 2008. More...
This will increase to over $9.5 billion in 2013, for a compound annual growth rate (CAGR) of 10.2%.

The market report, from BCC Research (Wellesley, MA, USA), is broken down into contrast reagents, optical reagents, and nuclear reagents. Of these, contrast reagents have the largest share of the market, worth an estimated $2.6 billion in 2008. This should increase to $3.7 billion in 2013, for a CAGR of 7.2%.

Nuclear reagents have the second largest market share, generating an estimated $2.1 billion in 2008. This is expected to increase at a CAGR of 12.5% to reach $3.7 billion in 2013. The third largest share of the market belongs to optical reagents, with sales of over $1.2 billion in 2008. This should reach $2.1 billion in 2013, for a CAGR of 12.1%.

Biologic imaging reagents play a fundamental role in current medical, pharmaceutical, and biotechnology industries. Optical imaging reagents allow life sciences researchers and drug developers to visualize and detect biologic processes at the molecular level and to perform key genomics, proteomics and cellular analysis assays. Nuclear and contrast reagents provide important diagnostic information to physicians, enabling the early detection and treatment of disease conditions in cardiology, neurology and oncology.

Technology and market forces are creating a key shift in biologic imaging reagents toward highly specific, multifunctional reagents, according to BBC Research analysts. This shift is creating opportunities for reagent manufacturers to address strategic market opportunities in genomics, proteomics, live cell imaging, early detection of cancers and neurological disorders, drug development, and hybrid imaging/therapeutic reagents.

A main competitive strategy for achieving success in biologic imaging reagents businesses has been acquiring unique technology in fluorescent proteins, fluorescence dyes and probes, quantum dots, and nanotechnology. A second route to gaining technologic competitive advantage is through strategic industry alliances.

BCC Research is a publisher of market research reports and technical publications.

Related Links:

BCC Research



Gold Member
12-Channel ECG
CM1200B
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Gas Analyzer
GE SAM
Blood Pressure Monitor
Cuff Blood Pressure Monitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.